David S. Snyder brings to Invenra over 25 years’ experience as the CFO of public and high growth companies. Mr. Snyder currently serves as the CFO/COO of Coya Therapeutics. Coya is a clinical-stage biotechnology company utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics to target disease, with an initial focus on neurodegenerative and autoimmune diseases. Prior to Coya, from late 2020 through 2021, Mr. Snyder served as the CFO of DisperSol Technologies, LLC where they were advancing two late-stage, small molecule drugs and using their proprietary KinetiSol platform to build a pipeline of NCEs. Prior to joining DisperSol, from 2014-2020 Snyder was the CFO of Exicure Inc. (Nasdaq: XCUR) a company developing nucleic acid therapeutics. From 2008 to 2014, he was the CFO of Cellular Dynamics, Inc. (Nasdaq: ICEL) a company developing iPSC-based stem cell tools and primary cell therapeutics. From 2007-2008, Mr. Snyder served as Senior Vice President of Finance, Site Vice President and Chief Financial Officer of Roche NimbleGen. Prior to 2007, Snyder was CFO of companies in real estate, software, and manufacturing. Early in his career Mr. Snyder worked for financial and real estate investor Sam Zell. He received his BA summa cum laude from Ottawa University and his M.B.A. with high honors from the Harvard Business School, where he was designated a George Fisher Baker Scholar.